Popular Articles

Dynavax Awarded Grant To Support Development Of TLR Inhibitors In Skin Diseases
Dynavax Technologies Corporation (Nasdaq:DVAX) announced the award of a Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID). This grant will support the preclinical development of Dynavax"s first-in-class oligonucleotide-based Toll-like Receptor (TLR) inhibitors for use in inflammatory skin diseases such as psoriasis, cutaneous lupus, and dermatomyositis. This new two-year $700,000 grant is in addition to a $1.8 million grant awarded in 2008.

A Selection Of Editorials And Opinions
Healing The Hospitals The Baltimore Sun
News of the day
Effects Of Once-Daily Tadalafil On Erectile Function In Men With Erectile Dysfunction And Signs And Symptoms Of Benign Prostatic Hyperplasia
UroToday.com - Men with benign prostatic hyperplasia (BPH) often suffer from lower urinary tract symptoms (LUTS; BPH-LUTS) such as urinary frequency, urgency, intermittency, nocturia, straining, incomplete emptying, or weak urinary stream. BPH-LUTS and erectile dysfunction (ED), both highly prevalent conditions in aging men, are frequently associated in the same men, may have common pathophysiological mechanisms, and contribute negatively to quality of life.